Trials / Suspended
SuspendedNCT07011550
Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer
- Status
- Suspended
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- M.D. Anderson Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To learn if the drug combination of BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab can help to control advanced or metastatic MSS-CRC.
Detailed description
Primary Objectives * To determine the safety of the combination of BMS-986340, nivolumab, trifluridine/tipiracil and bevacizumab. * To determine the objective response rate (ORR) of the BMS-986340, nivolumab, trifluridine/tipiracil and bevacizumab Secondary Objectives • To determine the progression-free survival (PFS), overall survival (OS) and duration of response (DOR) in participants with advanced or metastatic MSS-CRC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | Given by IV |
| DRUG | Bevacizumab | Given by IV |
| DRUG | BMS-986340 | Given by IV |
| DRUG | Trifluridine + Tipiracil | Given by PO |
Timeline
- Start date
- 2025-08-15
- Primary completion
- 2028-07-01
- Completion
- 2030-07-01
- First posted
- 2025-06-09
- Last updated
- 2026-03-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07011550. Inclusion in this directory is not an endorsement.